2024年港股18A生物科技行业洞察报告：抗体药物赛道现状分析及企业挖掘

Investment Rating - The report does not explicitly state an investment rating for the biotechnology industry, particularly the antibody drug sector. Core Insights - The antibody drug sector is experiencing significant growth, driven by advancements in technology and increasing demand for targeted therapies, especially in oncology [4][36]. - As of March 31, 2024, 64 biotechnology companies have completed listings under the Hong Kong Stock Exchange's Chapter 18A, with 48 in the pharmaceutical sector, highlighting the sector's expansion [4]. - The global pipeline for antibody drugs is rich, with 6,272 antibody drugs (including biosimilars) reported as of July 20, 2023, indicating a robust research and development environment [5][23]. Summary by Sections Antibody Drug Industry Insights - Antibody drugs are characterized by high specificity and uniformity, targeting specific molecular sites to minimize damage to non-target cells, particularly in cancer treatment [15][16]. - The market for antibody drugs in China grew from 28.8 billion yuan in 2019 to 103.3 billion yuan in 2023, with a compound annual growth rate (CAGR) of 37.7% [36]. R&D Pipeline Distribution - The global antibody drug pipeline is predominantly focused on oncology, with nearly 50% of the drugs targeting cancer [23]. - The top 10 companies by the number of IND and above antibody drug pipelines include Roche, AstraZeneca, and Bristol-Myers Squibb [23]. Market Size - The antibody drug market in China is projected to reach 353.6 billion yuan by 2028, with a CAGR of 27.9% from 2023 to 2028 [36]. Monoclonal Antibody Market Analysis - As of October 2023, 32 monoclonal biosimilars have been approved in China, with significant competition in the market, particularly for drugs like Bevacizumab [41]. ADC Drug Market Analysis - As of November 2023, there are 15 approved ADC drugs globally, with Kadcyla being the highest-selling at $2.44 billion in 2022 [52]. - The ADC drug sector is rapidly evolving, with 554 ADC drugs currently in clinical trials [52]. Bispecific Antibody Market Analysis - In 2023, four new bispecific antibodies were approved, contributing to a total sales of $8.33 billion for the year, with Roche leading the market [63]. Company Insights - Key companies in the antibody drug sector include Innovent Biologics, I-Mab Biopharma, and Hengrui Medicine, which are actively involved in the development of innovative therapies [71].